Another Drug Price Hike

Valeant Pharmaceuticals is criticized for jacking up the price of a drug used in assisted suicide.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, AYENAOut-of-control pharmaceutical price-hiking is in the news again. After a Congressional investigation into the practice of drugmaker Valeant Pharmaceuticals buying older heart medications and raising their prices exponentially, the firm is on the hot seat once again—this time for doubling the price of a decades-old sleeping pill that is now used in instances of assisted suicide. Doctors prescribe the pill, Seconal (secobarbital), in cases of physician-assisted suicide, which voters in California made legal starting this June. Valeant bought the rights to Seconal last February—a month after California legislators proposed legalizing physician-assisted suicide—and immediately raised its price from $1,500 to $,3000.

“It’s just pharmaceutical company greed,” David Grube, a family physician in Oregon, told KQED, the San Francisco-based public radio station that broke the story. “It’s not a complicated thing to make, there’s no research being done on it, there’s no development,” he added. “That to me is unconscionable.”

Valeant came under fire last year when the company inflated the prices of two heart medications by 200 percent and 500 percent. The House of Representatives is still investigating those cases of alleged price gouging, The New York Times reported.

“Valeant sets prices for drugs based on a number of factors,” the company told KQED in a statement. “When possible, we offer patient assistance programs to mitigate the effects of price adjustments and keep out-of-pocket costs affordable ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026, Issue 1

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Skip the Wait for Protein Stability Data with Aunty

Skip the Wait for Protein Stability Data with Aunty

Unchained Labs
Graphic of three DNA helices in various colors

An Automated DNA-to-Data Framework for Production-Scale Sequencing

illumina
Exploring Cellular Organization with Spatial Proteomics

Exploring Cellular Organization with Spatial Proteomics

Abstract illustration of spheres with multiple layers, representing endoderm, ectoderm, and mesoderm derived organoids

Organoid Origins and How to Grow Them

Thermo Fisher Logo

Products

Brandtech Logo

BRANDTECH Scientific Introduces the Transferpette® pro Micropipette: A New Twist on Comfort and Control

Biotium Logo

Biotium Launches GlycoLiner™ Cell Surface Glycoprotein Labeling Kits for Rapid and Selective Cell Surface Imaging

Colorful abstract spiral dot pattern on a black background

Thermo Scientific X and S Series General Purpose Centrifuges

Thermo Fisher Logo
Abstract background with red and blue laser lights

VANTAstar Flexible microplate reader with simplified workflows

BMG LABTECH